Juvisé Pharmaceuticals acquires rights to MS therapy Ponvory outside North America
Acquiring Company
Juvisé Pharmaceuticals
Acquired Company
Johnson & Johnson Innovative Medicine Ireland
ParisBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiotechnologyHealth CareMedicalMedical DeviceTherapeuticsDescription
Juvisé Pharmaceuticals, a French pharmaceutical company, has acquired the global rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. The rights were acquired from Actelion Pharmaceuticals, the therapy’s original developer and now part of Johnson & Johnson Innovative Medicine. This strategic acquisition aligns with Juvisé Pharmaceuticals' commitment to expanding its portfolio with strong development potential and providing essential medications to patients and specialist doctors.
Who to call at Juvisé Pharmaceuticals, and when
When Juvisé Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Juvisé Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Juvisé Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Juvisé Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Juvisé Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Johnson & Johnson Innovative Medicine Ireland?
Johnson & Johnson Innovative Medicine Ireland was acquired by Juvisé Pharmaceuticals, based in Paris. The deal was reported on April 2, 2024. Juvisé Pharmaceuticals, based in Paris, France, is a leading pharmaceutical company with a focus on enhancing patient care by providing access to treatments with high medical value. Juvisé Pharmaceuticals is privately held and operates in Biotechnology.
When did Juvisé Pharmaceuticals acquire Johnson & Johnson Innovative Medicine Ireland?
Juvisé Pharmaceuticals's acquisition of Johnson & Johnson Innovative Medicine Ireland was reported on April 2, 2024. Juvisé Pharmaceuticals, a French pharmaceutical company, has acquired the global rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Johnson & Johnson Innovative Medicine Ireland do?
Johnson & Johnson Innovative Medicine Ireland innovates with purpose to lead where medicine is going. Its ambition is to tackle the toughest health challenges, where patient need is highest. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.